Latest Mrna Podcast Episodes
AI risk assessments: Future-proofing your innovation when rules can change mid-game
At the Intersection of Science and Law - September 06, 2022 16:54 - 24 minutesPublished in Chambers Expert Focus. DLA Piper partner Danny Tobey is joined by Aviva Wein, Assistant General Counsel at Johnson & Johnson, to discuss how medical device and pharmaceutical companies are future-proofing their innovations in artificial intelligence as new regulations and risks aris...
Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer
The Lancet Oncology in conversation with - August 30, 2022 22:00 - 11 minutes ★★★★★ - 1 ratingEline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs. Read the full Review: The QT interval prolongation potential of anticancer and supportive drugs: a c...
Ignace Vergote and Maria Kyrgiou on gynaecological cancers
The Lancet Oncology in conversation with - July 25, 2022 22:00 - 10 minutes ★★★★★ - 1 ratingIgnace Vergote (Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium) and Maria Kyrgiou (Imperial College London, London, UK) discuss their Series papers on gynaecological cancers. Visit the Series hub: Gynaecological cancers Tell us what you thought about this episode Contin...
David J Pinato on SARS-CoV-2 omicron outcomes among patients with cancer
The Lancet Oncology in conversation with - June 30, 2022 09:00 - 5 minutes ★★★★★ - 1 ratingDavid J Pinato (Imperial College London, London, UK) discusses the OnCovid registry study on the outcomes of the SARS-CoV-2 omicron variant outbreak among patients with cancer in Europe. Read the full article: Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and ...
The rise of telehealth amid the COVID-19 pandemic
At the Intersection of Science and Law - June 01, 2022 20:14 - 38 minutesKristi Kung is joined by Greg Bodulovic to discuss digital health and its rise during the COVID-19 pandemic as well as advancements in technology that address healthcare access. See omnystudio.com/listener for privacy information.
The rise of global telehealth
At the Intersection of Science and Law - June 01, 2022 20:14 - 25 minutesDLA Piper partners Kristi Kung and Greg Bodulovic discuss the rise of telehealth amid the COVID-19 pandemic, as well as advancements in technology aiming to address disparate access to healthcare globally. See omnystudio.com/listener for privacy information.
Wilfred Ngwa, Beatrice Wiafe-Addai, and David Kerr on cancer in sub-Saharan Africa
The Lancet Oncology in conversation with - May 09, 2022 22:00 - 30 minutes ★★★★★ - 1 ratingWilfred Ngwa (Harvard Medical School, Boston, MA, USA; Johns Hopkins University, Baltimore, MD, USA; ICT University, Yaounde, Cameroon), Beatrice Wiafe-Addai (Peace and Love Hospital, Kumasi, Ghana), and David Kerr (University of Oxford, Oxford, UK) discuss the Lancet Oncology Commission on canc...
Georgios Lyratzopoulos on emergency presentation
The Lancet Oncology in conversation with - April 28, 2022 14:00 - 13 minutes ★★★★★ - 1 ratingGeorgios Lyratzopoulos (Institute of Epidemiology & Health Care at University College London, London, UK) discusses his population-based study on risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission. Read the full article: Risk fac...
Advising the advisor: Tips for navigating the life sciences and regulatory environment
At the Intersection of Science and Law - April 18, 2022 17:30 - 31 minutesDLA Piper managing partner Emilio Ragosa is joined by Kevin Sheridan, Joint Global Head of Healthcare Investment Banking at Jefferies LLC, to discuss the importance of advisors having an understanding of the life sciences industry in order to provide value-added advice on transactions, including...
Lisa Iezzoni on disabilities and cancer, and Jordan Marchak on mental health problems in young cancer survivors
The Lancet Oncology in conversation with - March 29, 2022 09:00 - 12 minutes ★★★★★ - 1 ratingLisa Iezzoni (Massachusetts General Hospital, Boston, MA, USA) discusses her Series paper on disabilities and cancer and Jordan Marchak (Children’s Healthcare of Atlanta, Atlanta, GA, USA) discusses her Review on surveillance of mental health problems in childhood, adolescent, and young adult ca...
The moral imperative: Balancing innovation, regulation and prescription drug availability
At the Intersection of Science and Law - March 21, 2022 17:34 - 30 minutesDLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability. See omnystudio....
Incentivizing diverse representation in clinical trials
At the Intersection of Science and Law - March 02, 2022 18:42 - 22 minutesDiverse representation in clinical trials is critical in achieving greater equity and better healthcare outcomes. DLA Piper's Kirsten Axelsen and Sarah Schick are joined by Shazia Ahmad, Senior Director and Head of Patient and Physician Services at UBC, to discuss the importance of regulatory in...
Rosie Bradley on early-stage breast cancer treatment
The Lancet Oncology in conversation with - February 28, 2022 23:00 - 4 minutes ★★★★★ - 1 ratingRosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression. Read the full article: Aromatase inhibito...
Yi-Long Wu and Caicun Zhou on non-small-cell lung cancer
The Lancet Oncology in conversation with - February 01, 2022 15:00 - 9 minutes ★★★★★ - 1 ratingProf Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer. Read the full articles: Sugemalimab versus placeb...
Rebecca Fitzgerald on Barrett's oesophagus surveillance
The Lancet Oncology in conversation with - January 31, 2022 23:00 - 7 minutes ★★★★★ - 1 ratingRebecca Fitzgerald (University of Cambridge, Cambridge, UK) discusses her Article on the use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance. Read the full article: Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surve...
Elysia Alvarez on adolescent and young adult cancer
The Lancet Oncology in conversation with - December 29, 2021 23:00 - 4 minutes ★★★★★ - 1 ratingElysia Alvarez (UC Davis Comprehensive Cancer Center, Sacramento, USA) discusses her Article on the analysis of the global burden of adolescent and young adult cancer in 2019. Read the full article: The global burden of adolescent and young adult cancer in 2019 Tell us what you thought about ...
The crossroad of science and law
At the Intersection of Science and Law - December 16, 2021 19:15 - 26 minutesDLA Piper’s Lucas Przymusinski and Raymond Williams are joined by Michael King, Vice President and Associate General Counsel at Jazz Pharmaceuticals, to discuss the benefits of medical and science backgrounds when litigating matters for pharmaceutical and medical device companies. See omnystudi...
Aju Mathew on cancer care in India
The Lancet Oncology in conversation with - November 29, 2021 23:00 - 6 minutes ★★★★★ - 1 ratingAju Mathew (Malankara Orthodox Syrian Church Medical College and Hospital, Kerala, India) discusses his Review on financial toxicity in cancer care in India. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00468-X/fulltext Tell us what you thought abo...
Social media’s impact on the life sciences industry
At the Intersection of Science and Law - November 08, 2021 19:47 - 34 minutesDLA Piper’s Chris Campbell and Jody Rhodes are joined by Sarah Heineman, Senior Assistant General Counsel at Bayer, to discuss how social media affects the public's view of medicine and science and how that in turn impacts the life sciences industry, including litigation. See omnystudio.com/lis...
Episode 1: A Second Opinion
Unite The Fight - November 06, 2021 17:00 - 2 hours ★★★★★ - 1 ratingFour local doctors and a nurse in Redding (Shasta County) California speak out on natural immunity, vaccine mandates, and other related issues. Click the link to donate if you want to support discussions like this. Support the show (https://venmo.com/code?user_id=3397690083770368536 https://ven...
David Pinato on cancer patients who recovered from SARS-CoV-2 infection
The Lancet Oncology in conversation with - November 04, 2021 11:00 - 8 minutes ★★★★★ - 1 ratingDavid Pinato (Imperial College London, Hammersmith Hospital, London, UK) discusses his Article on prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection. Read the full paper: https://www.thelancet.com/journals/lanonc/...
Episode 0: The School Walkout
Unite The Fight - November 02, 2021 04:00 - 14 minutes ★★★★★ - 1 ratingKatie & Author discuss their story of natural immunity to Covid, the California mandates, government overreach, and the October 18th school walkout they were integral in starting. Support the show (https://venmo.com/code?user_id=3397690083770368536 https://venmo.com/code?user_id=339769008377036...
James Glasbey on the effect of lockdowns on cancer surgery
The Lancet Oncology in conversation with - November 01, 2021 23:00 - 7 minutes ★★★★★ - 1 ratingJames Glasbey (UK NIHR Global Health Research Unit on Global Surgery, University of Birmingham, Birmingham, UK) discusses his Article on the effect of COVID-19 pandemic lockdowns on planned cancer surgery. Read the full paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)...
Understanding AI and its use in drug discovery
At the Intersection of Science and Law - October 05, 2021 21:08 - 31 minutesDLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines. See omnystudio.com/listener for privacy information.
Manju Sengar and Christopher Booth on essential cancer drugs
The Lancet Oncology in conversation with - September 27, 2021 22:00 - 11 minutes ★★★★★ - 1 ratingManju Sengar (Tata Memorial Centre, India) and Christopher Booth (Queen’s University Cancer Research Institute, Canada) discuss their Article on the comparison between cancer drugs deemed essential by oncologists and those included in the WHO Essential Medicines List. Read the full paper: htt...
mRNA technology and the COVID-19 vaccine: A conversation with Pfizer’s Kathy Fernando
At the Intersection of Science and Law - September 03, 2021 16:45 - 26 minutesFor decades, scientists have studied the seemingly endless possibilities of custom-made messenger RNA, or mRNA. Kathy Fernando, Head Vice President, Worldwide of Clinical Operations at Pfizer, spent her early bench science career working with mRNA technology and had a front row seat to the creat...
Susannah Stanway, Richard Cowan, Danielle Rodin, and Miriam Mutebi on helping with cancer control in LMICs
The Lancet Oncology in conversation with - August 31, 2021 22:00 - 28 minutes ★★★★★ - 1 ratingSusannah Stanway (UK Global Cancer Network), Richard Cowan (Christie NHS Foundation Trust, UK), Danielle Rodin (Princess Margaret Cancer Centre, Canada), and Miriam Mutebi (Aga Khan University Hospital, Kenya) discuss the Global Cancer Control Networks Series on how high-income countries, partic...
Harriet Rumgay on the burden of cancer attributable to alcohol
The Lancet Oncology in conversation with - July 30, 2021 22:00 - 6 minutes ★★★★★ - 1 ratingHarriet Rumgay (International Agency for Research on Cancer, France) discusses the recent global burden of cancer in 2020 attributable to alcohol consumption study. Read the full paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00279-5/fulltext Tell us what you thought...
Rafael Cardoso and Hermann Brenner on colorectal cancer
The Lancet Oncology in conversation with - June 28, 2021 22:00 - 6 minutes ★★★★★ - 1 ratingRafael Cardoso and Hermann Brenner (German Cancer Research Center, Heidelberg, Germany) discuss their recent paper on colorectal cancer incidence, mortality, and stage distribution in Europe. Read the full paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00199-6/fullte...
Takayuki Yoshino on the DESTINY-CRC01 trial
The Lancet Oncology in conversation with - June 01, 2021 22:00 - 5 minutes ★★★★★ - 1 ratingTakayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fu...